ClinicalTrials.gg
CompletedNCT06413537Updated May 26, 2026Results posted

Study of SPG601 in Adult Men With Fragile X Syndrome

A Phase 2 interventional study of SPG601 and Placebo in Fragile X Syndrome, sponsored by Spinogenix. Completed at 1 site in United States. Open to male participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Spinogenix · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 82 studies in Fragile X Syndrome with a site in United States — 11 open to participants now, 16 under way, 2 of them phase 3. Fragile X Syndrome · United States.

Enrollment
62nd of 68
10 · median 60
Started
2024
with 1 other
Phase 2
28 of 82
2 open now
Registered
76th of 82
by date

Among the 82 studies in Fragile X Syndrome with a site in United States, this one is the 62nd largest by enrollment of the 68 interventional ones that give a count, is one of 2 that started in 2024, is one of 28 in phase 2, and was the 76th registered.

Fragile X Syndrome

115 studies on the registry are indexed under Fragile X Syndrome; 25 are open to participants now.

Browse Fragile X Syndrome studies →

Open to participants now

11 of the 82 studies in Fragile X Syndrome with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Fragile X Syndrome studies recruiting now, 5 (28%) set no upper age limit and 13 (72%) stop at 75 or younger; 15 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 45 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Fragile X Syndrome with a site in United States, or all of them as a file.
02

Study summary

This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, pharmacokinetics and pharmacodynamics of SPG601 in adult men with Fragile X syndrome.

Read the detailed description

This study is a Phase 2 randomized, double blind, placebo-controlled, cross over, single dose of SPG601 and matching Placebo in patients with Fragile X syndrome.

This study will entail 2 in person clinic visits to administer oral doses of SPG601 or matching placebo. Participants will receive a dose of either SPG601 or placebo at first visit, and will cross over to receive the other product at the second visit.

03

Conditions studied

  • Fragile X Syndrome

Browse trials for

Keywords

  • Fragile X Syndrome
  • Fragile X Chromosome
  • cognitive outcomes
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult males aged 18 to 45 years
  • Diagnosis of Fragile X as confirmed with genetic testing
  • Patient must have caregiver
  • Must be in good health with no significant medical history
  • Clinical laboratory values within normal range or \< 1.2 times
  • use by men or women consistent with local regulations
  • Able and willing to provide written
  • Stable dosing of psychotropic drugs for at least 4 weeks

Exclusion criteria

Exclusion Criteria:

  • Any physical or psychological condition that prohibits study completion
  • Uncontrolled seizures or history of epilepsy with a seizure in the past 6 months.
  • Auditory or visual impairments that can not be corrected
  • History of suicidal behavior or suicidal ideation
  • Screening vital signs that are abnormal per protocol specification
  • that are abnormal
  • History of substance abuse or dependence within 6 months
  • Other products within 30 days
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
10 participants (actual)

Study arms

  • Active comparator
    Experimental: Active SPG601 to be administered to participants with Fragile X Syndrome

    Participants with Fragile X Syndrome will be randomized to receive SPG601 or placebo (8 capsules of 100 mg) one time on days 1 and 8 of the study.

    Drug: SPG601

  • Placebo comparator
    Placebo Comparator: Placebo comparator to be administered to participants with Fragile X Syndrome

    Participants with Fragile X Syndrome will be randomized to receive SPG601 or placebo (8 capsules of 100 mg) one time on days 1 and 8 of the study.

    Drug: Placebo

Interventions

  • DrugSPG601

    synthetic small molecule

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Clinical Global Impressions Improvement Scale as Determined by the Treating Clinician

    Change in clinician rated measures on scale of 1 to 7, higher value indicates more severe symptom presentation

    Time frame: 15 days

  2. Clinical Global Impressions Improvement Scale as Determined by the Caregiver

    Change in caregiver rated measures on scale of 1 to 7, higher value indicates more severe symptom presentation

    Time frame: 15 days

  3. Visual Analog Scale as Determined by the Patient Caregiver

    Change from baseline in notation on Visual Analog scale as determined by the patient caregiver. Rater will indicate on linear measurement scale of 1 to 100 centimeters, with higher score indicating more severe symptoms

    Time frame: 15 days

  4. Change in Auditory Response to Chirp Stimulus

    Auditory test will be evaluated for difference in responses to stimuli, as demonstrated by the Inter-Trial Coherence (ITC). ITC is a measure of phase consistency across trials, expressed as a dimensionless value ranging from 0 to 1. A value of 0 indicates completely random phase across trials, while 1 denotes a perfectly phase-locked response across trials. Higher ITC values reflect greater phase consistency of neural oscillations. ITC is a unit of measure as frequency (40Hz) vs time (msec).

    Time frame: 15 days

Secondary outcomes

  1. Change From Baseline in Attention and Inhibition Symptoms-Go/NoGo Subtest

    KiTAP Tests of Attentional Performance for Children, to measure alertness and assessments of visual reactions. The Go-NoGo subtest measures impulsivity by requiring subjects to tap a button when the target stimulus is presented, while refraining from hitting the button for the non-target stimulus. Summary statistics presented for change in reaction time from baseline.

    Time frame: 15 days

  2. Change in Cognitive Outcomes Measured by NIH Cognitive Toolbox

    National Institute of Health (NIH)- Toolbox Cognitive Battery (TCB): A series of tests will be conducted to assess reading, vocabulary, and speed matching. These tests are scored from zero to 100. A higher score indicate better performance.

    Time frame: 15 days

  3. Change in Memory and Cognitive Assessment With RBANS List Learning.

    RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) is scored from -4 to 4, with higher values indicate higher memory and cognitive assessment

    Time frame: 15 days

  4. Change in Auditory Response to Steady State Auditory Stimuli From Baseline

    Auditory test will be evaluated for difference in responses to stimuli. Auditory Steady State Response (ASSR) is measured following a short stream of click trains with a 500 msec inter-train interval (duration), at standard tone and at 40Hz tone. The magnitude of ITC represents the phase consistency of oscillatory activities. ITC is a measure of phase consistency across trials, expressed as a dimensionless value ranging from 0 to 1. A value of 0 indicates completely random phase across trials, while 1 denotes a perfectly phase-locked response across trials. Higher ITC values reflect greater phase consistency of neural oscillations. ITC as a unit of measure is expressed as frequency (40Hz) vs time (msec)

    Time frame: 15 days

  5. Safety and Tolerability of SPG601 in Patients With Fragile X Syndrome

    Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Time frame: 15 days

  6. Change From Baseline in Attention and Inhibition Symptoms-Flexibility Subtest

    The KiTAP is a computerized executive function battery that consists of eight nonverbal subtests measuring different basal as well as higher-order components of attention and executive functioning. The alertness subtest requires subjects to tap a button every time a stimulus appears on the screen. Mean reaction time was measured over 90 seconds and change from baseline was calculated. A lower reaction time (net decrease in reaction time) indicates better performance.

    Time frame: 15 days

  7. Change From Baseline in Attention and Inhibition Symptoms-Alertness Subtest

    KiTAP Tests of Attentional Performance for Children, to measure alertness and assessments of visual reactions. The alertness subtest records the number of times a subject taps a button when a stimulus appears on screen. Change in Baseline summary statistics for reaction time presented below. A lower number indicates lower reaction time and better performance.

    Time frame: 15 days

  8. Change From Baseline in Attention and Inhibition Symptoms-Distractability Subtest

    The KiTAP is a computerized executive function battery that consists of eight nonverbal subtests measuring components of attention and executive functioning. The distractibility subtest measures how easily the subject is distracted by extraneous stimuli. This subtest requires subjects to tap a button when a target stimulus appears on the screen while ignoring distractions. Mean number of correct responses were recorded, and change from baseline was calculated, and a higher mean number of correct responses indicates better performance.

    Time frame: 15 days

  9. Change in Eye Tracking for Social Gaze

    This test will measure eye tracking and movement in response to stimuli, and social gaze version, with a Likert scale of 1-5 for behavior rating.

    Time frame: 15 days

  10. Change in Eye Tracking Measured by Electroretinography

    This test will measure the electrical activity in the retina in response to stimuli, evaluating change in stimuli response post dose minus stimuli pre dose-RIGHT EYE

    Time frame: 15 days

  11. Change in Eye Tracking Measured by Electroretinography

    This test will measure the electrical activity in the retina in response to stimuli, evaluating change in stimuli response post dose minus stimuli pre dose-LEFT EYE

    Time frame: 15 days

07

Results

Posted May 26, 2026

Participant flow

Participant flow — Overall Study
MilestoneSequence 1: SPG601 First, Placebo SecondSequence 2: Placebo First SPG601 Second
Started55
Completed55
Not completed00

Outcome measures

PrimaryClinical Global Impressions Improvement Scale as Determined by the Treating Clinician

Change in clinician rated measures on scale of 1 to 7, higher value indicates more severe symptom presentation

Time frame:
15 days
Reported as:
Mean · score on a scale
Clinical Global Impressions Improvement Scale as Determined by the Treating Clinician
score on a scaleExperimental: Active SPG601 to be Administered to Participants With Fragile X SyndromePlacebo Comparator: Placebo Comparator to be Administered to Participants With Fragile X Syndrome
Clinical Global Impressions Improvement Scale as Determined by the Treating Clinician3.7 (3.106 to 4.07)3.8 (3.399 to 4.26)
PrimaryClinical Global Impressions Improvement Scale as Determined by the Caregiver

Change in caregiver rated measures on scale of 1 to 7, higher value indicates more severe symptom presentation

Time frame:
15 days
Reported as:
Mean · score on a scale
Clinical Global Impressions Improvement Scale as Determined by the Caregiver
score on a scaleExperimental: Active SPG601 to be Administered to Participants With Fragile X SyndromePlacebo Comparator: Placebo Comparator to be Administered to Participants With Fragile X Syndrome
Clinical Global Impressions Improvement Scale as Determined by the Caregiver2.9 (1.1 to 3.6)2.8 (1.16 to 3.8)
PrimaryVisual Analog Scale as Determined by the Patient Caregiver

Change from baseline in notation on Visual Analog scale as determined by the patient caregiver. Rater will indicate on linear measurement scale of 1 to 100 centimeters, with higher score indicating more severe symptoms

Time frame:
15 days
Reported as:
Mean · score on a scale
Visual Analog Scale as Determined by the Patient Caregiver
score on a scaleExperimental: Active SPG601 to be Administered to Participants With Fragile X SyndromePlacebo Comparator: Placebo Comparator to be Administered to Participants With Fragile X Syndrome
Visual Analog Scale as Determined by the Patient Caregiver-6.5 (-18.61 to 4.408)-6 (-16.25 to 5.334)
PrimaryChange in Auditory Response to Chirp Stimulus

Auditory test will be evaluated for difference in responses to stimuli, as demonstrated by the Inter-Trial Coherence (ITC). ITC is a measure of phase consistency across trials, expressed as a dimensionless value ranging from 0 to 1. A value of 0 indicates completely random phase across trials, while 1 denotes a perfectly phase-locked response across trials. Higher ITC values reflect greater phase consistency of neural oscillations. ITC is a unit of measure as frequency (40Hz) vs time (msec).

Time frame:
15 days
Reported as:
Mean · Inter Trial Coherence
Change in Auditory Response to Chirp Stimulus
Inter Trial CoherenceExperimental: Active SPG601 to be Administered to Participants With Fragile X SyndromePlacebo Comparator: Placebo to be Administered to Participants With Fragile X Syndrome
Change in Auditory Response to Chirp Stimulus-0.012 ± 0.0410.014 ± 0.062
SecondaryChange From Baseline in Attention and Inhibition Symptoms-Go/NoGo Subtest

KiTAP Tests of Attentional Performance for Children, to measure alertness and assessments of visual reactions. The Go-NoGo subtest measures impulsivity by requiring subjects to tap a button when the target stimulus is presented, while refraining from hitting the button for the non-target stimulus. Summary statistics presented for change in reaction time from baseline.

Time frame:
15 days
Reported as:
Mean · milliseconds
Change From Baseline in Attention and Inhibition Symptoms-Go/NoGo Subtest
millisecondsExperimental: Active SPG601 to be Administered to Participants With Fragile X SyndromePlacebo Comparator: Placebo Comparator to be Administered to Participants With Fragile X Syndrome
Change From Baseline in Attention and Inhibition Symptoms-Go/NoGo Subtest67.8 (-87.63 to 220.4)-17.6 (-145.8 to 112.6)
SecondaryChange in Cognitive Outcomes Measured by NIH Cognitive Toolbox

National Institute of Health (NIH)- Toolbox Cognitive Battery (TCB): A series of tests will be conducted to assess reading, vocabulary, and speed matching. These tests are scored from zero to 100. A higher score indicate better performance.

Time frame:
15 days
Reported as:
Mean · score on a scale
Change in Cognitive Outcomes Measured by NIH Cognitive Toolbox
score on a scaleExperimental: Active SPG601 to be Administered to Participants With Fragile X SyndromePlacebo Comparator: Placebo Comparator to be Administered to Participants With Fragile X Syndrome
Change in Cognitive Outcomes Measured by NIH Cognitive Toolbox15.5 (-2.098 to 41.05)1.7 (-26.52 to 23.13)
SecondaryChange in Memory and Cognitive Assessment With RBANS List Learning.

RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) is scored from -4 to 4, with higher values indicate higher memory and cognitive assessment

Time frame:
15 days
Reported as:
Mean · score on a scale
Change in Memory and Cognitive Assessment With RBANS List Learning.
score on a scaleExperimental: Active SPG601 to be Administered to Participants With Fragile X SyndromePlacebo Comparator: Placebo Comparator to be Administered to Participants With Fragile X Syndrome
Change in Memory and Cognitive Assessment With RBANS List Learning.1.7 (-.546 to 3.879)3.8 (.7873 to 5.213)
SecondaryChange in Auditory Response to Steady State Auditory Stimuli From Baseline

Auditory test will be evaluated for difference in responses to stimuli. Auditory Steady State Response (ASSR) is measured following a short stream of click trains with a 500 msec inter-train interval (duration), at standard tone and at 40Hz tone. The magnitude of ITC represents the phase consistency of oscillatory activities. ITC is a measure of phase consistency across trials, expressed as a dimensionless value ranging from 0 to 1. A value of 0 indicates completely random phase across trials, while 1 denotes a perfectly phase-locked response across trials. Higher ITC values reflect greater phase consistency of neural oscillations. ITC as a unit of measure is expressed as frequency (40Hz) vs time (msec)

Time frame:
15 days
Reported as:
Mean · ITC
Change in Auditory Response to Steady State Auditory Stimuli From Baseline
ITCExperimental: Active SPG601 to be Administered to Participants With Fragile X SyndromePlacebo Comparator: Placebo to be Administered to Participants With Fragile X Syndrome
Change in Auditory Response to Steady State Auditory Stimuli From Baseline-0.012 ± 0.04170.014 ± 0.0615
SecondarySafety and Tolerability of SPG601 in Patients With Fragile X Syndrome

Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)

Time frame:
15 days
Reported as:
Number · participants
Safety and Tolerability of SPG601 in Patients With Fragile X Syndrome
participantsExperimental: Active SPG601 to be Administered to Participants With Fragile X SyndromePlacebo Comparator: Placebo Comparator to be Administered to Participants With Fragile X Syndrome
Safety and Tolerability of SPG601 in Patients With Fragile X Syndrome10
SecondaryChange From Baseline in Attention and Inhibition Symptoms-Flexibility Subtest

The KiTAP is a computerized executive function battery that consists of eight nonverbal subtests measuring different basal as well as higher-order components of attention and executive functioning. The alertness subtest requires subjects to tap a button every time a stimulus appears on the screen. Mean reaction time was measured over 90 seconds and change from baseline was calculated. A lower reaction time (net decrease in reaction time) indicates better performance.

Time frame:
15 days
Reported as:
Mean · milliseconds
Change From Baseline in Attention and Inhibition Symptoms-Flexibility Subtest
millisecondsExperimental: Active SPG601 to be Administered to Participants With Fragile X SyndromePlacebo Comparator: Placebo Comparator to be Administered to Participants With Fragile X Syndrome
Change From Baseline in Attention and Inhibition Symptoms-Flexibility Subtest-61.8 (-356.6 to 207)-103.4 (-330.5 to 142.3)
SecondaryChange From Baseline in Attention and Inhibition Symptoms-Alertness Subtest

KiTAP Tests of Attentional Performance for Children, to measure alertness and assessments of visual reactions. The alertness subtest records the number of times a subject taps a button when a stimulus appears on screen. Change in Baseline summary statistics for reaction time presented below. A lower number indicates lower reaction time and better performance.

Time frame:
15 days
Reported as:
Mean · milliseconds
Change From Baseline in Attention and Inhibition Symptoms-Alertness Subtest
millisecondsExperimental: Active SPG601 to be Administered to Participants With Fragile X SyndromePlacebo Comparator: Placebo Comparator to be Administered to Participants With Fragile X Syndrome
Change From Baseline in Attention and Inhibition Symptoms-Alertness Subtest129.4 (-142.4 to 402)-133 (-405.5 to 138.8)
SecondaryChange From Baseline in Attention and Inhibition Symptoms-Distractability Subtest

The KiTAP is a computerized executive function battery that consists of eight nonverbal subtests measuring components of attention and executive functioning. The distractibility subtest measures how easily the subject is distracted by extraneous stimuli. This subtest requires subjects to tap a button when a target stimulus appears on the screen while ignoring distractions. Mean number of correct responses were recorded, and change from baseline was calculated, and a higher mean number of correct responses indicates better performance.

Time frame:
15 days
Reported as:
Mean · correct responses
Change From Baseline in Attention and Inhibition Symptoms-Distractability Subtest
correct responsesExperimental: Active SPG601 to be Administered to Participants With Fragile X SyndromePlacebo Comparator: Placebo Comparator to be Administered to Participants With Fragile X Syndrome
Change From Baseline in Attention and Inhibition Symptoms-Distractability Subtest-54.7 (-173.6 to 93.29)45.94 (-63.14 to 155)
SecondaryChange in Eye Tracking for Social Gaze

This test will measure eye tracking and movement in response to stimuli, and social gaze version, with a Likert scale of 1-5 for behavior rating.

Time frame:
15 days

No measurements were reported for this outcome.

SecondaryChange in Eye Tracking Measured by Electroretinography

This test will measure the electrical activity in the retina in response to stimuli, evaluating change in stimuli response post dose minus stimuli pre dose-RIGHT EYE

Time frame:
15 days
Reported as:
Mean · milli volts
Change in Eye Tracking Measured by Electroretinography
milli voltsExperimental: Active SPG601 to be Administered to Participants With Fragile X SyndromePlacebo Comparator: Placebo to be Administered to Participants With Fragile X Syndrome
Change in Eye Tracking Measured by Electroretinography-1.35 ± 1.78-1.15 ± 3.11
SecondaryChange in Eye Tracking Measured by Electroretinography

This test will measure the electrical activity in the retina in response to stimuli, evaluating change in stimuli response post dose minus stimuli pre dose-LEFT EYE

Time frame:
15 days
Reported as:
Mean · milli volts
Change in Eye Tracking Measured by Electroretinography
milli voltsExperimental: Active SPG601 to be Administered to Participants With Fragile X SyndromePlacebo Comparator: Placebo to be Administered to Participants With Fragile X Syndrome
Change in Eye Tracking Measured by Electroretinography-2.16 ± 4.88.03 ± 2.05

Adverse events

Collected over Adverse event data was collected at study visits that happened weekly for 3 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental: Active SPG601 to be Administered to Participants With Fragile X Syndrome0/10 (0%)0/10 (0%)1/10 (10%)
Placebo Comparator: Placebo Comparator to be Administered to Participants With Fragile X Syndrome0/10 (0%)0/10 (0%)0/10 (0%)
Most frequent other events
Most frequent other events
EventExperimental: Active SPG601 to be Administered to Participants With Fragile X SyndromePlacebo Comparator: Placebo Comparator to be Administered to Participants With Fragile X Syndrome
exacerbation of ticPsychiatric disorders1/100/10

Baseline characteristics

Adult men with Fragile X syndrome; cross-over study and all study participants were randomized to receive active drug or placebo at first study visit, and received other treatment allocation at subsequent study visit

Age, Categorical
Age, Categorical(Participants)The Study Was a Crossover Trial of Two Treatments Administered at Day 1 and Day 8 of the Study.
<=18 years0
Between 18 and 65 years10
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)The Study Was a Crossover Trial of Two Treatments Administered at Day 1 and Day 8 of the Study.
Female0
Male10
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)The Study Was a Crossover Trial of Two Treatments Administered at Day 1 and Day 8 of the Study.
Hispanic or Latino0
Not Hispanic or Latino10
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)The Study Was a Crossover Trial of Two Treatments Administered at Day 1 and Day 8 of the Study.
United States10
08

Study locations

1 site
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Dec 2024, 5 months.

Results were first posted in May 2026, 1 year 4 months after primary completion.

Of 15 phase 2 interventional studies under Fragile X Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 37. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2024
First posted
May 14, 2024
StartActual
Jul 5, 2024
Primary completionActual
Dec 31, 2024
CompletionActual
Dec 31, 2024
Results first posted
May 26, 2026
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06413537
Lead sponsor
Spinogenix
Collaborators
Avance Clinical Pty Ltd.
Responsible party
Sponsor
First posted
May 14, 2024
Start date
Jul 5, 2024
Primary completion
Dec 31, 2024
Completion
Dec 31, 2024
Results posted
May 26, 2026
Last update
May 26, 2026

Study contacts

Craig Erickson, MD
principal investigator · Children's Hospital Medical Center, Cincinnati

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion